Last reviewed · How we verify

NCT03814954

Nebulized Epinephrine vs. Salbutamol in Bronchiolitis Among Children

Completed NA Last updated 30 August 2022
What this trial tests

NA trial testing Salbutamol in Respiratory Distress Score in 90 participants. Completed in 31 August 2021.

Timeline
1 January 2019
Primary endpoint
31 August 2021
31 August 2021

Quick facts

Lead sponsorMakassed General Hospital
PhaseNA
StatusCompleted
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingsingle
Primary purposetreatment
Enrollment90
Start date1 January 2019
Primary completion31 August 2021
Estimated completion31 August 2021
Sites1 location across Lebanon

Drugs / interventions tested

Conditions studied

Sponsor

Makassed General Hospital

Who can join

Adults 1 Month to 24 Months, any sex, with Respiratory Distress Score. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Acute bronchiolitis, mostly secondary to infection due to Respiratory syncytial virus (RSV) is very common in infants under two years old. It is usually benign. However, the dyspnea it causes is a big concern for parents and this disease can take a severe form on certain particular ground thus constituting a frequent reason for hospitalization in pediatrics. Nebulized epinephrine showed more efficacy than nebulized salbutamol.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Salbutamol

Trials testing the same drug.

Other Makassed General Hospital trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03814954.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing